Management of the older person with atrial fibrillation

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 57, Issue 6, 2002, Pages

  Aronow, Wilbert S ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DILTIAZEM; VERAPAMIL; WARFARIN;

CARDIOVERSION; ELDERLY CARE; HEART ATRIUM FIBRILLATION; HUMAN; PACEMAKER; PRIORITY JOURNAL; REVIEW; STROKE; SYNCOPE; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TREATMENT OUTCOME; TREATMENT PLANNING; VERTIGO;

THROMBUS;

EID: 0036259005     PISSN: 10795006     EISSN: None     Source Type: Journal    
DOI: 10.1093/gerona/57.6.M352     Document Type: Review

References (134)

1. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study
2. Prevalence of atrial fibrillation and association of atrial fibrillation with prior and new thromboembolic stroke in older patients
3. Prevalence and incidence of cardiovascular disease in 1160 older men and 2464 older women in a long-term health care facility
4. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study)
5. Underutilization of warfarin in older persons with chronic nonvalvular atrial fibrillation at high risk for developing stroke
6. Incidence of and risk factors for atrial fibrillation in older adults
7. Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm
8. High-density mapping of electrically induced atrial fibrillation in humans
9. A focal source of atrial fibrillation treated by discrete radiofrequency ablation
10. Pathophysiology and prevention of atrial fibrillation
11. Echocardiographic findings associated with atrial fibrillation in 1,699 patients aged >60 years
12. Low serum thyrotropin concentration as a risk factor for atrial fibrillation in older persons
13. Epidemiologic features of chronic atrial fibrillation: The Framingham Study
14. Impact of atrial fibrillation on the risk of death. The Framingham Heart Study
15. Correlation of atrial fibrillation, paroxysmal supraventricular tachycardia, and sinus rhythm with incidences of new coronary events in 1,359 patients, mean age 81 years, with heart disease
16. Acute myocardial infarction complicated by atrial fibrillation in the elderly: Prevalence and outcomes
17. New atrial fibrillation after acute myocardial infarction independently predicts death: The GUSTO-III experience
18. Atrial fibrillation and mortality among patients with acute coronary syndromes without ST-segment elevation: Results from the PURSUIT trial
19. Correlation of paroxysmal supraventricular tachycardia, atrial fibrillation, and sinus rhythm with incidences of new thromboembolic stroke in 1,476 old-old patients
20. Association of left ventricular hypertrophy and chronic atrial fibrillation with the incidence of new thromboembolic stroke in 2,384 older persons
21. Association of extracranial carotid arterial disease and chronic atrial fibrillation with the incidence of new thromboembolic stroke in 1,846 older persons
22. Paroxysmal atrial fibrillation: High frequency of embolic brain infarction in elderly autopsy patients
23. Silent cerebral infarction in patients with nonrheumatic atrial fibrillation
24. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomic and symptomatic left ventricular systolic dysfunction: A retrospective analysis of the SOLVD trials
25. Prognosis of congestive heart failure after prior myocardial infarction in older persons with atrial fibrillation versus sinus rhythm
26. Tachycardia-induced cardiomyopathy: A review of animal models and clinical studies
27. Rate issues in atrial fibrillation: Consequences of tachycardia and therapy for rate control
28. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: A meta-analysis
29. Tachycardia-related cardiomyopathy: A common cause of ventricular dysfunction in patients with atrial fibrillation referred for atrioventricular ablation
30. Pacemaker therapy in patients with atrial fibrillation
31. Treatment of arrhythmias with pindolol
32. Acebutolol in supraventricular arrhythmias
33. Use of beta-adrenergic blockers in antiarrhythmic therapy
34. Efficacy and safety of esmolol vs propranolol in the treatment of supraventricular tachyarrhythmias: A multicenter double-blind clinical trial
35. Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter
36. Verapamil in atrial fibrillation and atrial flutter
37. Digoxin for converting recent onset atrial fibrillation to sinus rhythm: A randomized, double-blinded trial
38. Digoxin for atrial fibrillation: A drug whose time has gone?
39. Digoxin or angiotensin converting enzyme inhibitors for congestive heart failure in geriatric patients: Which is the preferred treatment?
40. Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: Beneficial effect of an added beta adrenergic blocking agent
41. Efficacy and safety of medium- and high-dose diltiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation
42. Superiority of oral verapamil therapy to digoxin in treatment of chronic atrial fibrillation
43. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: A crossover open-label study of five drug regimens
44. Amiodarone for refractory atrial fibrillation
45. Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter
46. Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: The effect of digoxin
47. Double-blind placebo controlled trial of digoxin in symptomatic paroxysmal atrial fibrillation
48. Failure of long-term digitalization to prevent rapid ventricular response in patients with paroxysmal atrial fibrillation
49. Effects of digoxin on acute, atrial fibrillation-induced changes in atrial refractoriness
50. Long-term follow-up after radiofrequency modification of the atrioventricular node in patients with atrial fibrillation
51. Control of rapid ventricular response by radiofrequency catheter modification of the atrioventricular node in patients with medically refractory atrial fibrillation
52. Quality of life and outcomes after radiofrequency His-bundle catheter ablation and permanent pacemaker implantation: Impact of treatment in paroxysmal and established atrial fibrillation
53. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation. A randomized, controlled study
54. Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation
55. Successful surgical treatment of atrial fibrillation: Review and clinical update
56. Sinus node-atrioventricular node isolation: Long-term results with the "Corridor" operation for atrial fibrillation
57. Outcome of valve repair and the Cox maze procedure for mitral regurgitation and association atrial fibrillation
58. The Cox-Maze procedure: The Cleveland Clinic experience
59. Results of maze surgery for lone paroxysmal atrial fibrillation
60. Limited posterior left atrial cryoablation in patients with chronic atrial fibrillation undergoing valvular heart surgery
61. Electrophysiological end point for catheter ablation of atrial fibrillation initiated from multiple pulmonary venous foci
62. Catheter maze-ablation for preventing atrial fibrillation: Where do we stand?
63. Atrioverter: An implantable device for the treatment of atrial fibrillation
64. Chronic atrial fibrillation and stroke in paced patients with sick sinus syndrome. Relevance of clinical characteristics and pacing modalities
65. Prospective randomised trial of atrial versus ventricular pacing in sick-sinus syndrome
66. Prevalence of arrhythmias detected by 24-hour ambulatory electrocardiography and value of antiarrhythmic therapy in elderly patients with unexplained syncope
67. Long-term prevention of vagal atrial arrhythmias by atria pacing at 90/minute: Experience with 6 cases
68. Atrial pacing periablation for prevention of paroxysmal atrial fibrillation
69. Randomized prospective pilot study of long-term dual-site atrial pacing for prevention of atrial fibrillation
70. Dual-site atrial pacing for atrial fibrillation in patients without bradycardia
71. Randomized controlled study investigating the effect of biatrial pacing in prevention of atrial fibrillation after coronary artery bypass grafting
72. Treatment of underlying atrial fibrillation: Paced rhythm obscures recognition
73. Clinical perspectives in management of Wolff-Parkinson-White syndrome. Part 2: Diagnostic evaluation and treatment strategies
74. Catheter ablation of accessory atrioventricular pathways (Wolff-Parkinson-White syndrome) by radiofrequency current
75. Catheter ablation of accessory pathways, atrioventricular nodal reentrant tachycardia, and the atrioventricular junction. Final results of a prospective, multicenter clinical trial
76. Electrical conversion of atrial fibrillation: Immediate and long-term results and selection of patients
77. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive summary
78. Transthoracic cardioversion of atrial fibrillation. Comparison of rectilinear biphasic versus damped sine wave monophasic shocks
79. Possible atrial proarrhythmic effects of class IC antiarrhythmic drugs
80. Proarrhythmia in patients treated for atrial fibrillation or flutter
81. Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital
82. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction
83. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter
84. Dofetilide in patients with congestive heart failure and left ventricular dysfunction
85. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: A dose-response study
86. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment
87. Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: Final results of a prospective 4.5-year study
88. Antithrombotic therapy in atrial fibrillation
89. Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: Evidence for "atrial stunning" as a mechanism of thromboembolic complications
90. Exclusion of atrial thrombus by transesophageal echocardiography does not preclude embolism after cardioversion of atrial fibrillation: A multicenter study
91. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation
92. Left atrial appendage "stunning" after spontaneous conversion of atrial fibrillation demonstrated by transesophageal Doppler echocardiography
93. Strategies for cardioversion of atrial fibrillation - Time for a change?
94. Cardioversion in patients with atrial fibrillation and left atrial thrombi on initial transesophageal echocardiography: Should transesophageal echocardiography be repeated before elective cardioversion? A cost-effectiveness analysis
95. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: A meta-analysis of randomized control trials
96. Effect of quinidine or procainimide versus no antiarrhythmic drug on sudden cardiac death, total cardiac death, and total death in elderly patients with heart disease and complex ventricular arrhythmias
97. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation
98. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation
99. Amiodarone to prevent recurrence of atrial fibrillation
100. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation. A randomized double-blind, placebo controlled study
101. Antiarrhythmic effects of azimilide in atrial fibrillation: Efficacy and dose-response
102. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation
103. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: An overview of results from randomized controlled trials
104. The CASCADE study: Randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle
105. Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation
106. Effect of propranolol versus no antiarrhythmic drug on sudden death, total cardiac death, and total death in patients ≥62 years of age with heart disease, complex ventricular arrhythmias, and left ventricular ejection fraction ≥40%
107. Management of atrial fibrillation after coronary artery bypass graft
108. Rhythm or rate control in atrial fibrillation - Pharmacological intervention in atrial fibrillation (PIAF): A randomised trial
109. Atrial fibrillation follow-up investigation of rhythm management - The AFFIRM Study design
110. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation
111. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials
112. Risk factors for new thromboembolic stroke in persons ≥62 years old with chronic atrial fibrillation
113. Risk factors for thromboembolic stroke in elderly patients with chronic atrial fibrillation
114. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk
115. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial
116. Effect of warfarin versus aspirin on the incidence of new thromboembolic stroke in older persons with chronic atrial fibrillation and abnormal and normal left ventricular ejection fraction
117. Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk
118. Risk factors for thromboembolic complications in chronic atrial fibrillation
119. Association of mitral annular calcium with new thromboembolic stroke at 44-month follow-up of 2,148 persons, mean age 81 years
120. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke
121. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation
122. Preliminary report of the Stroke Prevention in Atrial Fibrillation Study
123. Stroke Prevention in Atrial Fibrillation Study: Final results
124. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study
125. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation
126. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study
127. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation. Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study
128. Incidence of new thromboembolic stroke in persons ≥62 years old with chronic atrial fibrillation treated with warfarin versus aspirin
129. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin. Stroke Prevention in Atrial Fibrillation III Study
130. Cardiovascular drug therapy in the elderly
131. Antithrombotic therapy in atrial fibrillation
132. The natural history of lone atrial fibrillation. A population-based study over three decades
133. Characteristics and prognosis of lone atrial fibrillation. 30-Year follow-up in the Framingham Study
134. Adverse outcomes and predictors of underuse of antithrombotic therapy in Medicare beneficiaries with chronic atrial fibrillation